PET developer Naviscan announced that its Japanese distributor, SCETI, has received notification of reimbursement approval for Naviscan's positron emission mammography (PEM) scanner.
The Japanese Ministry of Health, Labor, and Welfare granted the reimbursement effective July 1. The reimbursement criterion is based on the additional resolution and specificity obtained on PEM that cannot be determined in a typical whole-body PET/CT exam, Naviscan said. SCETI expects this approval will open the market and allow them to build on their installed base of clinical systems in Japan.
